LH: Leadership change

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D., the current Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, with responsibility for the Company's Early Development Research Laboratories and Central Laboratories businesses. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LABCORP HOLDINGS INC. Registrant Date: August 14, 2026 By: /s/ KATHRYN W. KYLE Kathryn W. Kyle Executive Vice President, Chief Legal Officer and Corporate Secretary